Yuko Mizuma – GM, Hong Kong & Macau, Eli Lilly Asia, Inc.
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Company information:
Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Address: 27/F, Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong
Tel.: (+852) 2851 8029
Website: http://hybribio.com/
Email: marketing@hybribio.com
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Drawing on an extensive management background in telecom, IT, and digital, Vincent Ma now serves as CEO of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). He outlines the under-construction…
Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology…
OASES was established to position Hong Kong as a global innovation and technology hub, with significant investments in infrastructure and funding, particularly focusing on life and health sciences, AI, fintech,…
One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing…
A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s…
The City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education. Michael Yang, Senior VP of Innovation and Enterprise, professor of…
Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the…
Dr Juliana Chan, one of Asia’s leading endocrinologists, is also the founding director of GemVCare, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and…
Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom…
Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the…
Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in…
See our Cookie Privacy Policy Here
